BACKGROUND: Chronic rhinosinusitis (CRS) has been defined as inflammation of the paranasal sinuses lasting at least 12 weeks with corresponding 2 or more "cardinal symptoms" that include: (1) nasal obstruction; (2) thick nasal discharge; (3) facial pain/pressure; and (4) reduction or loss of sense of smell. Although prior studies have investigated symptoms of CRS after sinus surgery, none have compared the outcomes of these specific symptoms to ongoing medical therapy. METHODS: Patients with CRS were prospectively enrolled into a multi-institutional, comparative effectiveness, cohort study. Subjects elected either continued medical management or endoscopic sinus surgery (ESS). Baseline characteristics and objective clinical findings were collected. Cardinal symptoms of CRS were operationalized by 4 questions on the 22-item Sino-Nasal Outcome Test (SNOT-22). Symptom improvement was evaluated in subjects with at least 6-month follow-up. RESULTS: A total of 342 subjects were enrolled, with 69 (20.2%) electing continued medical management, whereas 273 (79.8%) elected ESS. Subjects electing surgical therapy were more likely to have a higher baseline aggregate SNOT-22 score (44.3 (18.9) vs 53.6 (18.8); p < 0.001). All subjects improved across all cardinal symptoms; however, subjects undergoing ESS were significantly more likely (p ≤ 0.013) to experience improvement in thick nasal discharge (odds ratio [OR] = 4.36), facial pain/pressure (OR = 3.56), and blockage/congestion of nose (OR = 2.76). Subjects with nasal polyposis were significantly more likely to report complete resolution of smell/taste following ESS compare to medical management (23.8% vs 4.0%; p = 0.026). CONCLUSION: Across a large population, surgical management is more effective at resolving the cardinal symptoms of CRS than ongoing medical management with the exception of sense of smell/taste.
BACKGROUND:Chronic rhinosinusitis (CRS) has been defined as inflammation of the paranasal sinuses lasting at least 12 weeks with corresponding 2 or more "cardinal symptoms" that include: (1) nasal obstruction; (2) thick nasal discharge; (3) facial pain/pressure; and (4) reduction or loss of sense of smell. Although prior studies have investigated symptoms of CRS after sinus surgery, none have compared the outcomes of these specific symptoms to ongoing medical therapy. METHODS:Patients with CRS were prospectively enrolled into a multi-institutional, comparative effectiveness, cohort study. Subjects elected either continued medical management or endoscopic sinus surgery (ESS). Baseline characteristics and objective clinical findings were collected. Cardinal symptoms of CRS were operationalized by 4 questions on the 22-item Sino-Nasal Outcome Test (SNOT-22). Symptom improvement was evaluated in subjects with at least 6-month follow-up. RESULTS: A total of 342 subjects were enrolled, with 69 (20.2%) electing continued medical management, whereas 273 (79.8%) elected ESS. Subjects electing surgical therapy were more likely to have a higher baseline aggregate SNOT-22 score (44.3 (18.9) vs 53.6 (18.8); p < 0.001). All subjects improved across all cardinal symptoms; however, subjects undergoing ESS were significantly more likely (p ≤ 0.013) to experience improvement in thick nasal discharge (odds ratio [OR] = 4.36), facial pain/pressure (OR = 3.56), and blockage/congestion of nose (OR = 2.76). Subjects with nasal polyposis were significantly more likely to report complete resolution of smell/taste following ESS compare to medical management (23.8% vs 4.0%; p = 0.026). CONCLUSION: Across a large population, surgical management is more effective at resolving the cardinal symptoms of CRS than ongoing medical management with the exception of sense of smell/taste.
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinology Date: 2012-03 Impact factor: 3.681
Authors: Timothy L Smith; Jamie R Litvack; Peter H Hwang; Todd A Loehrl; Jess C Mace; Karen J Fong; Kenneth E James Journal: Otolaryngol Head Neck Surg Date: 2010-01 Impact factor: 3.497
Authors: Adam S DeConde; Jess C Mace; Vijay R Ramakrishnan; Jeremiah A Alt; Timothy L Smith Journal: Laryngoscope Date: 2017-08-04 Impact factor: 3.325
Authors: Edward El Rassi; Jess C Mace; Toby O Steele; Jeremiah A Alt; Zachary M Soler; Rongwei Fu; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2015-12-01 Impact factor: 3.858
Authors: Adam S DeConde; Jeffrey D Suh; Jess C Mace; Jeremiah A Alt; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2015-04-23 Impact factor: 3.858
Authors: Andrew J Thomas; Jess C Mace; Vijay R Ramakrishnan; Jeremiah A Alt; Jose L Mattos; Rodney J Schlosser; Zachary M Soler; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2020-02-03 Impact factor: 3.858
Authors: Rodney J Schlosser; Kristina Storck; Bernadette M Cortese; Thomas W Uhde; Luke Rudmik; Zachary M Soler Journal: Am J Rhinol Allergy Date: 2016 Mar-Apr Impact factor: 2.467
Authors: Rodney J Schlosser; Kristina A Storck; Luke Rudmik; Timothy L Smith; Jess C Mace; Jose Mattos; Zachary M Soler Journal: Int Forum Allergy Rhinol Date: 2016-08-23 Impact factor: 3.858